Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
System to significantly increase the effective yield of Calcium (and other alloying elements) in the treatment of specialty steels, while reducing impurities in the melt. (HOT-WIRE)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: United Kingdom,France,United Kingdom,Belgium,Germany,Portugal,United Kingdom
Call:  (FP7-SME-2012, 2012)
Start date: 2013-01-01
End date: 2014-12-31
Duration (months): 24.0
Total project cost (EUR): 1596459.2
EU funding (EUR): 1211998.0
Participants: 7
Project status: CLOSED

Hotwire aims to develop a new, specially coated feed wire and dispensing system that is able to delay initial Ca core exposure from current duration of only 1.5 seconds to ~5 seconds, extend the Ca melt time (once exposed) from <1 second to ~3 seconds, through the application of thin, nano-particle enhanced heat resistant/intumescent coatings. To further increase the yield of the Calcium by enabling a wider dispersion area in the ladle by developing a novel, articulating feed head to allow wire feed across the entire ladle cross-section.

Keywords: steel,nanotechnology,calcium,wire,ladle
Advanced Microwave Plasma Gasification of pig and cow manure for cost-effective biogas generation. (PLAGASMIC)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: United Kingdom,France,Romania,United Kingdom,Ireland,Spain
Call:  (FP7-SME-2012, 2012)
Start date: 2012-09-01
End date: 2014-08-31
Duration (months): 24.0
Total project cost (EUR): 1482071.2
EU funding (EUR): 1135000.0
Participants: 6
Project status: CLOSED

The livestock sector in Europe is facing a problem: The manure it generates cannot all be used as fertiliser because excessive amounts of manure to land can lead to surface and ground water contamination through the accumulation of minerals in the soil, as manure contains high amounts of nitrogen and phosphorus. The EU has legislated to place severe restrictions on the quantity of organic manure that can be applied to land (170 kg N/ha/year). Farmers are facing increasing costs to export manure off-farms the current level of spreadlands is inadequate to meet the limits. There is an urgent need for the livestock farming community to develop a method of removal and reuse of animal manure such that the economic and legislative burden on them may ease through the development of an environmentally-friendly technology. Current technologies require very high capital investment that is out of reach of most of the farming community. Our project involves the pyrolysis of manure using microwave induced plasma (MIP) technology allowing a rapid release of biogas.

Keywords: pyrolysis,microwave,farm,waste,agriculture,environment,manure
Competitive stationary low concentrating solar module of novel design (SOLGAIN)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: Lithuania,Lithuania,Spain,United Kingdom,Poland,Italy
Call:  (FP7-SME-2012, 2012)
Start date: 2012-10-01
End date: 2014-09-30
Duration (months): 24.0
Total project cost (EUR): 1618362.0
EU funding (EUR): 929000.0
Participants: 8
Project status: CLOSED

The achievement of the goals of the European energy and climate change policy necessitates the development and deployment of a diverse portfolio of low carbon energy technologies. In 2010, photovoltaic (PV) technology was the leading renewable energy technology in terms of capacity growth in Europe. But for reaching the main sectorial target: “up to 15% of the EU electricity will be generated by solar energy in 2020” it is a pre-requisite to achieve the substantial reduction of costs and the improvement of device efficiencies. Recent developments in PV worldwide business are showing that other global economies are fiercely fighting to take over EU leadership in the production of the PV products as well as technology. EU could maintain a competitive position due to introduction of new cost-effective photovoltaic technologies underpinned by strong RTD efforts allowing European companies to develop innovative knowledge intensive solutions through whole supply chain to capture market share. The biggest influences on the cost effectiveness of the conversion of cells to modules are the optimisation of cell efficiency and material consumption and the optimisation of the combined module manufacturing and installation cost. The proposed project aims to bring the innovative photovoltaic technology enabling achievement of 0,67 €/W cost target in next two years. To achieve this goal proposers will develop innovative concepts for key components of PV system, prototype and test the stationary low concentrating photovoltaic module of novel design. The proposed solutions enable higher conversion efficiency and 5-fold reduction of active material – both leading to significant cost/performance, resulting more than 20% reduction of the Watt-peak. By creating a non-competitive supply chain within the consortium the SME partners will be able to use the new technology developed to secure their competitive advantage in PV markets and over 10 year’s period make a cumulative profit of about 27 M€.

Keywords: low concentrating photovoltaic module,prism coupled compound parabola,nanocomposite material,tio2,c-si,back side copper contact solar cell,nanocomposite,self-formed nanostructures
PHYTOCHEMICALS TO REDUCE NITRITE IN MEAT PRODUCTS (PHYTOME)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SME associations
Action type: Research for the benefit of specific groups
Countries involved: Netherlands,United Kingdom,Italy,Belgium,Greece,Netherlands,Belgium,Netherlands,Netherlands,Italy,Belgium
Call:  (FP7-SME-2012, 2012)
Start date: 2012-12-01
End date: 2015-11-30
Duration (months): 36.0
Total project cost (EUR): 3063322.5
EU funding (EUR): 2387000.0
Participants: 12
Project status: CLOSED

Trend analyses indicate that the consumption of meat products in most EU countries is stagnating, with the exception of the market segment ‘light and healthy’. However, consumer perception is increasingly influenced by messages in the media that consumption of nitrite preserved meat products contributes to human cancer risk. Therefore, the aim of the PHYTOME project is to develop new meat processing technologies, resulting in innovative products that have no or strongly reduced nitrite levels and that have been shown to contribute to improved gut health. The new meat products will be enriched with carefully selected biologically active compounds, so called phytochemicals, present in various natural plant extracts. Specific phytochemicals possess antimicrobial activity that may allow replacement of nitrite without hampering microbiological safety. Phytochemicals are also known to protect the gut from the induction of genetic damage and adverse health effects. The PHYTOME project will deliver optimized food processing techniques to introduce phytochemicals into a range of meat products and that will guarantee microbiological safety and good sensory quality. These new technologies will be transferred to the other end-users to demonstrate their applicability in industrial settings. The new meat products will be evaluated in a human dietary intervention study to establish their positive effect on cancer risk markers in colonic tissues using the newest genomics techniques available. Elaborate consumer studies will show the response to the newly developed products. Both consumer acceptance and the willingness to buy this new type of products will be tested, eventually resulting in a tailored marketing strategy. The European and national SME associations have an excellent network to disseminate the results of the PHYTOME project across the entire EU meat processing sector, stimulating the exploitation of the identified growth market for ‘light and healthy’ meat products.

Keywords: meat processing technology,phytochemicals,food safety,natural plant extracts,public health promotion,genomics
Quantum Dot Technologies for Extended Reach Nodes In Access Networks (QUATERNIAN)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: Ireland,United Kingdom,Germany,Spain,Ireland,United Kingdom,Greece
Call:  (FP7-SME-2012, 2012)
Start date: 2013-02-01
End date: 2015-06-30
Duration (months): 29.0
Total project cost (EUR): 1111805.5
EU funding (EUR): 826000.0
Participants: 8
Project status: CLOSED

The QUATERNIAN project will use quantum-dot laser technology to expand the product ranges and support the competitive position of European SMEs selling into optical access network markets. Access networks based on optical technologies are rapidly growing, as traditional copper based networking proves overly complex, energy inefficient and has high maintenance cost. With the advent of high-speed mobile computing devices, broadband connectivity is required both through fixed connections at the premises and through wireless connections. The latter requirement is often not provided by carrier networks as deep building penetration is incompatible with wide area cell networks. The QUATERNIAN project will advance the position of SMEs supplying equipment both for rapidly growing high-speed wired optical access networks and high-speed radio-over-fibre (RoF) building access networks. Quantum Dot laser materials grown on Gallium Arsenide substrates give a generational advance in the control of the carrier density of states. This material advance has led to significant device technology advances in the critical wavelength range of 1.1 to 1.3 microns. This wavelength range is crucial both for low-cost wired passive optical networks and advanced multiple antenna systems. The research performing partners are leaders in the study and development of quantum dot devices and systems. Through the QUATERNIAN proposal these research performing institutions will assist these high-growth SMEs in the adoption and further development of quantum dot technology. The QUATERNIAN project strengthens the competitiveness of the European economy, the sustainability of the European research area and maintains European technology leadership.

Keywords: quantum dots,semiconductor lasers,optical communications
Chemotherapy guidance based on efficacy of treatment regimen in cancer cells from the individual patient (CHEMOGUIDE)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Demonstration Activity
Action type: Collaborative project
Countries involved: Spain,Denmark,Germany,United States
Call:  (FP7-SME-2012, 2012)
Start date: 2013-04-01
End date: 2015-06-30
Duration (months): 27.0
Total project cost (EUR): 1597720.0
EU funding (EUR): 1043000.0
Participants: 5
Project status: CLOSED

The ChemoGuide project will clinically validate a proto-type technology (2treat) developed in the previous “Research for SMEs” project, “Integrated Chemical Synthesis and Cell screening in patient cells (ICSC). The project will execute a clinical study to evaluate the 2treat test’s capability of predicting which combination therapy that is most efficacious and show no resistance in the individual colorectal cancer patient. The prediction is based on reading the cell functional output cancer cells isolated from the individual patient. The clinical study will serve to verify the capability and robustness of the 2treat test. The 2treat test is formatted as an easy-to-use, disposable test array. Colorectal cancer is now the most diagnosed cancer in EU, and the prognosis of especially stage III and IV patients is very poor. The 2treat test is expected to provide a major benefit to these patients by significantly improving the Prognosis Free Survival (PFS). Importantly oncologist will be provided the first technology that is capable of testing the cell-functional output of all combination treatment regimens used for treatment of colorectal cancer in Europe and USA before a first line treatment is launched. The technology will both improve treatment quality for the individual patient and raise the cost efficiency providing a positive impact on the health care systems.

Keywords: colorectal cancer individual chemotherapy screening clinical trial prognostic
WHEYLAYER2: barrier biopolymers for sustainable packaging (WHEYLAYER 2)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Demonstration Activity
Action type: Collaborative project
Countries involved: Slovenia,Spain,Germany,Italy,Germany,Ireland
Call:  (FP7-SME-2012, 2012)
Start date: 2012-08-01
End date: 2014-07-31
Duration (months): 24.0
Total project cost (EUR): 3044660.0
EU funding (EUR): 1755945.0
Participants: 10
Project status: CLOSED

The WHEYLAYER 2 project is based on the WHEYLAYER project that has been recognized by the EC as a star project with high dissemination potential and has received a lot of interest from the packaging industry and its end users. The WHEYLAYER project developed a biopolymer-coating based on pure whey protein isolates for plastic films able to replace currently used expensive synthetic oxygen barrier. WHEYLAYER reached Oxygen Transmission Rate (OTR, Q100) of 1 cm3/m2 d bar at 23ºC and 50% RH and Water Vapour Transmission Rate (WVTR, Q100) of 2 g/m² d. The WHEYLAYER material is easily recyclable, the LCA showed significant reduction of the resulting packaging environmental impact, and preliminary evaluation showed that it fulfilled food safety regulations (migration, emission of volatile compounds). A patent application was filled regarding the coating process and a WHEYLAYER prototype application machine was built that reaches semi-industrial production speed while keeping satisfactory barrier properties. WHEYLAYER 2 will focus on up-scaling the results obtained in WHEYLAYER project, proving their industrialisation potential. It will focus on final packaging items (trays, blisters, tubes and cans as opposed to films and sheets in the WHEYLAYER project) and additional specific functionalities (e.g. convertibility, printability, UV barrier). Main markets evaluated will be cosmetics and pharmaceutical packaging in addition to food. Since WHEYLAYER exceeds the barrier properties of existing biopolymer and due to the pull for recyclable packaging, the market opportunties for WHEYLAYER appear huge as a potential substitute for EVOH and PVDC. The WHEYLAYER technology will result in recyclable multilayer packaging. WHEYLAYER2 will be heavily disseminated while maximasing the exploitability of the material and finally fill the gap for environmentally friendly packaging materials for sensitive products meeting the expectations of the increasing amount of "green" consumers.

Keywords: whey,wpc,wpi,biopolymer,recyclable,polymer,packaging,food,cosmetic,pharmaceutical,market
Translational Kinase Tumour Inhibitor discovery Consortium (TAKTIC)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SMEs
Action type: Research for the benefit of specific groups
Countries involved: Sweden,France,Italy,France,Israel,Germany
Call:  (FP7-SME-2012, 2012)
Start date: 2013-02-01
End date: 2015-03-31
Duration (months): 26.0
Total project cost (EUR): 1477337.0
EU funding (EUR): 1148997.0
Participants: 6
Project status: CLOSED

Protein kinases are involved in the control of a large number of cellular processes and play a central role in human physiology. More than 500 genes encoding protein kinases have been identified in the human genome, and it is estimated that about 30% of all human proteins may be phosphorylated by kinases. Deficiency in kinase activity has implications in cancer, central nervous system disorders, autoimmune diseases and immunosuppression, diabetes, osteoporosis and various metabolic disorders. Small-molecule kinase inhibitors have therefore moved into the focus of the pharmaceutical industry as a new class of drugs, which is expected to produce new and more efficient treatments and grow significantly within the coming decade. The proposed project brings together the unique and proprietary technologies of three SMEs and the expertise of academic research partners to create a new platform for lead compound discovery with a focus on protein kinases. Three kinases will be targeted for the development of inhibitory compounds. The academic partners will contribute a modern high throughput platform for protein expression and crystallisation (Israel Structural Proteomics Centre), and expertise in the biochemistry and biology of the targeted kinases combined with the principles of the use of bioisosterism in synthesis of novel chemical compounds (University of Turin). The applied principles and technologies will provide new IP opportunities for the partner SMEs in the otherwise crowded kinase inhibitor IP space and will help in the design of new strategies in the discovery of inhibitors for novel kinase targets in the treatment of cancer. The generated compounds will be sold and/or out-licensed to large pharmaceutical companies for continued development. This market is currently undergoing continuous expansion due to large cuts in early drug discovery within most pharmaceutical companies.

Keywords: kinase drug discovery,translational research,cancer therapy,lead discovery centre
Support to the Chair and Vice-Chairs of the ERC Scientific Council 2012 (ERCSC-CHAIRS-SUP2012)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: MSCA other
Action type: Coordination and support actions
Countries involved: Austria
Call:  (FP7-Adhoc-2007-13, 2007)
Start date: 2012-01-01
End date: 2012-12-31
Duration (months): 12.0
Total project cost (EUR): 322800.0
EU funding (EUR): 299270.0
Participants: 1
Project status: CLOSED

The proposed Action will provide the necessary support to the Chair and Vice-Chairs of the European Research Council Scientific Council (ERC ScC) to achieve key milestones and deliverables of the ScC, which are required in the fifth year of implementation of the Ideas specific programme. Under the Seventh Research Framework Programme (FP7) and the Ideas specific programme, the Commission has established the European Research Council providing a competitive funding mechanism for investigator-driven frontier research on European level. One of the key structural components of the ERC is the Scientific Council consisting of 22 researchers at the highest level, representative of a large range of disciplines and institutional backgrounds and acting independently. The ERC ScC establishes and oversees the ERC's scientific management and the implementation of the Work Programme, including the peer review and the selection of peer reviewers. The proposed project aims to support the ScC Chair and Vice-Chairs in the efficient and timely achievement of the ScC’s objectives in 2012. It will support and assist Professor Helga Nowotny, Chair of the ERC’s ScC, Professor Pavel Exner, and Professor Carl-Henrik Heldin, Vice-Chairs of the ERC’s ScC, in their diverse responsibilities which include the achievement of efficient and effective functioning of the ScC, its integrated operation together with the ERC Executive Agency (ERCEA), and effective interfacing with the scientific community, other funding agencies and the political institutions of the European Union. The project will provide administrative and research support ranging from secretarial tasks to assistance in developing policy papers related to the work of the Chair and Vice-Chairs of the ERC ScC for a period of one year.

Keywords: erc scientific council support for 2012
One Health approach to integrate Guadeloupe research on vector-borne and emerging diseases in the ERA: from characterization of emergence mechanisms to innovative approaches for prediction and control (EPIGENESIS)

Framework: FP7 — Capacities
Programme: Research Potential
Destination: Unlocking and developing the Research Potential of research entities established in the EU�s Convergence regions and Outermost Regions
Action type: Coordination and support actions
Countries involved: France
Call:  (FP7-REGPOT-2012-2013-1, 2012)
Start date: 2013-09-01
End date: 2016-08-31
Duration (months): 36.0
Total project cost (EUR): 5482207.0
EU funding (EUR): 3526011.0
Participants: 1
Project status: CLOSED

Infectious emerging diseases involving arthropod vectors or vertebrate hosts threaten human health and stock breeding worldwide and respond fast and strongly to global change (intense travel and trade, natural hazards, societal and climate change…), particularly in the Caribbean with increased risk of diseases outbreak. Anticipation of health crises through relevant research programmes and innovative disease-control strategies is thus necessary to preserve animal health, food security and human health in interconnected Caribbean territories and Europe. The objective is to expand Guadeloupe research potential on emerging and vector-borne diseases along the ‘One-Health’ concept to improve the capacity of prediction and decision makers’ anticipation. The project will rely on an integrated approach, from genomics to surveillance and prevention strategies based on interdisciplinary analysis, aimed at facilitating the adoption of new knowledge by all stakeholders. Specific objectives are: (i) reinforce Guadeloupe S&T potential on emerging and vector-borne diseases through the acquisition of a biosecurity laboratory Level 3 and recruitment of experienced scientists; (ii) develop strategic partnerships with outstanding European research entities (exchange of scientists, training); (iii) disseminate scientific information and knowledge to the scientific community, decision-makers and the public, (publications, meetings, web site); (iv) increase Guadeloupe innovation potential (diagnostic, vaccines, surveillance tools). Sustainability will be ensured by paving the way for a Caribbean centre of excellence on emerging and vector-borne diseases, in collaboration with CaribVET and European partners. It will result in a better integration in the ERA for the research community and upgraded RTD capacity. With support of the regional authorities and Structural Funds, it will contribute to regional development: alert system for disease outbreak, path to smart specialisation.

Keywords: guadeloupe,innovation,prediction,anticipation,control,vector,diseases,health,emergence,governance